Syndax Pharmaceuticals, Inc. (SNDX)Healthcare | Biotechnology | New York, United States | NasdaqGS
19.54 USD
-0.62
(-3.075%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 19.39 -0.15 (-0.150%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 4:19 a.m. EDT
Syndax presents a classic 'value trap' scenario where aggressive analyst targets and biotech hype clash with deteriorating financial reality. While the company boasts a 92% revenue surge, the bottom line is bleeding heavily, with gross and operating margins deeply negative and a massive cash burn that has eroded equity to a fraction of book value. The balance sheet is precarious, with debt significantly outweighing cash reserves, creating a high-risk environment for a small-cap biotech. The recent price action shows some resilience, trading near its 50-day average, but the statistical forecast offers no directional clarity, reflecting the asset's high noise-to-signal ratio. The options market confirms this tension, with heavy speculation on both a miraculous recovery and a catastrophic failure, but the fundamental fundamentals—specifically the inability to generate profit or cover debt—are currently too weak to support a confident long-term entry. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.065575 |
| AutoTheta | 0.067145 |
| AutoETS | 0.067176 |
| AutoARIMA | 0.067176 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 42% |
| H-stat | 0.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.124 |
| Excess Kurtosis | -0.71 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3903.451 |
| Revenue per Share | 2.873 |
| Market Cap | 1,731,440,000 |
| Forward P/E | -23.95 |
| Beta | 0.37 |
| Profit Margins | -87.52% |
| Website | https://syndax.com |
As of Aug. 22, 2026, 4:19 a.m. EDT: Speculators are positioning for significant volatility rather than a specific directional breakout. Call Open Interest is heavily skewed out-of-the-money (OTM) at strikes like $22 and $26, suggesting bets on a sharp rally, while Put Open Interest clusters deep OTM at $12-$17, indicating a hedge against a crash. However, the lack of substantial volume in the deep ITM puts and the massive IV spike on distant $8 calls suggest the market is pricing in a binary event or extreme uncertainty rather than a steady trend. The net positioning is defensive with a speculative upside bias.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.2121588 |
| Address1 | 730 Third Avenue |
| Address2 | 9th Floor |
| All Time High | 29.86 |
| All Time Low | 3.39 |
| Ask | 24.94 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,101,910 |
| Average Daily Volume3 Month | 1,794,958 |
| Average Volume | 1,794,958 |
| Average Volume10Days | 1,101,910 |
| Beta | 0.373 |
| Bid | 14.19 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 0.169 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 19.54 |
| Current Ratio | 6.772 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 20.045 |
| Day Low | 19.47 |
| Debt To Equity | 3,903.451 |
| Display Name | Syndax Pharmaceuticals |
| Earnings Call Timestamp End | 1,785,873,600 |
| Earnings Call Timestamp Start | 1,785,873,600 |
| Earnings Timestamp | 1,785,873,600 |
| Earnings Timestamp End | 1,793,649,600 |
| Earnings Timestamp Start | 1,793,649,600 |
| Ebitda | -194,160,000 |
| Ebitda Margins | -0.76971 |
| Enterprise To Ebitda | -9.168 |
| Enterprise To Revenue | 7.056 |
| Enterprise Value | 1,779,981,056 |
| Eps Current Year | -1.93483 |
| Eps Forward | -0.81594 |
| Eps Trailing Twelve Months | -2.43 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 20.8713 |
| Fifty Day Average Change | -1.3312988 |
| Fifty Day Average Change Percent | -0.063786104 |
| Fifty Two Week Change Percent | 21.21588 |
| Fifty Two Week High | 25.59 |
| Fifty Two Week High Change | -6.049999 |
| Fifty Two Week High Change Percent | -0.23642045 |
| Fifty Two Week Low | 12.99 |
| Fifty Two Week Low Change | 6.550001 |
| Fifty Two Week Low Change Percent | 0.50423414 |
| Fifty Two Week Range | 12.99 - 25.59 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,456,929,000,000 |
| Float Shares | 80,295,047 |
| Forward Eps | -0.81594 |
| Forward P E | -23.94784 |
| Free Cashflow | -150,078,624 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 298 |
| Fullday Change | -0.619999 |
| Fullday Change Percent | -3.07539 |
| Fullday Price | 19.39 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | -0.08007 |
| Gross Profits | -20,198,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01687 |
| Held Percent Institutions | 1.26188 |
| Implied Shares Outstanding | 88,610,027 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York. |
| Long Name | Syndax Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,731,440,000 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_27240138 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -220,764,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,801,122,224 |
| Number Of Analyst Opinions | 11 |
| Open | 19.98 |
| Operating Cashflow | -220,640,000 |
| Operating Margins | -0.54947 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 781 419 1400 |
| Post Market Change | -0.15000153 |
| Post Market Change Percent | -0.76766384 |
| Post Market Price | 19.39 |
| Post Market Time | 1,787,959,806 |
| Previous Close | 20.16 |
| Price Eps Current Year | -10.099079 |
| Price Hint | 2 |
| Price To Book | 115.62131 |
| Price To Sales Trailing12 Months | 6.863957 |
| Profit Margins | -0.87518 |
| Quick Ratio | 6.291 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.619999 |
| Regular Market Change Percent | -3.07539 |
| Regular Market Day High | 20.045 |
| Regular Market Day Low | 19.47 |
| Regular Market Day Range | 19.47 - 20.045 |
| Regular Market Open | 19.98 |
| Regular Market Previous Close | 20.16 |
| Regular Market Price | 19.54 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 1,042,312 |
| Return On Assets | -0.18673 |
| Return On Equity | -2.55925 |
| Revenue Growth | 0.918 |
| Revenue Per Share | 2.873 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 88,610,027 |
| Shares Percent Shares Out | 0.2565 |
| Shares Short | 22,902,431 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 20,816,110 |
| Short Name | Syndax Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.2609 |
| Short Ratio | 15.85 |
| Source Interval | 15 |
| State | NY |
| Symbol | SNDX |
| Target High Price | 57.0 |
| Target Low Price | 26.0 |
| Target Mean Price | 37.54545 |
| Target Median Price | 37.0 |
| Total Cash | 554,265,984 |
| Total Cash Per Share | 6.207 |
| Total Debt | 589,382,016 |
| Total Revenue | 252,251,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 20.891525 |
| Two Hundred Day Average Change | -1.3515244 |
| Two Hundred Day Average Change Percent | -0.06469247 |
| Type Disp | Equity |
| Volume | 1,042,312 |
| Website | https://syndax.com |
| Zip | 10,017 |